Neurofeedback Platforms Market Forecasts to 2034 – Global Analysis By Component (Hardware, Software and Services), Modality, Platform Type, Age Group, Application , End User, and By Geography
According to Stratistics MRC, the Global Neurofeedback Platforms Market is accounted for $1.3 billion in 2026 and is expected to reach $3.4 billion by 2034 growing at a CAGR of 12.7% during the forecast period. Neurofeedback platforms refer to integrated clinical and consumer systems that measure real-time brain electrical activity through EEG, functional magnetic resonance imaging, hemoencephalography, or slow cortical potential recording, and provide immediate auditory, visual, or haptic feedback signals that train users to self-regulate specific neural oscillation patterns associated with attention, relaxation, cognitive performance, and neurological symptom management. These platforms encompass electrode headsets, signal amplification hardware, real-time signal processing software, gamified training interfaces, session management portals, and progress tracking analytics serving ADHD treatment, anxiety management, peak performance training, and post-traumatic stress disorder therapies.
Market Dynamics:
Driver:
ADHD and Mental Health Treatment Demand
Escalating ADHD and mental health treatment demand is the primary driver expanding neurofeedback platform adoption as clinicians and patients seek non-pharmacological, side-effect-free interventions for attention deficit disorders, anxiety, and depression that medication-resistant patient populations particularly require. FDA clearance of neurofeedback-based ADHD treatments has established regulatory legitimacy that is expanding insurance reimbursement coverage and physician referral confidence. Growing parental preference for non-stimulant ADHD interventions for pediatric patients is generating strong consumer demand for certified clinical neurofeedback programs that creates sustained platform procurement growth across clinical psychology and pediatric neurology practice settings.
Restraint:
Clinical Evidence and Reimbursement Gaps
Inconsistent clinical evidence quality and limited insurance reimbursement coverage represent significant adoption barriers as neurofeedback platform operators struggle to secure payer coverage without the randomized controlled trial evidence bases that health technology assessment bodies require for positive coverage determinations. Heterogeneity of neurofeedback protocols, electrode placement standards, and outcome measurement approaches across clinical studies limits meta-analytic evidence synthesis that would strengthen reimbursement advocacy. High out-of-pocket session costs in markets without coverage create access barriers that confine neurofeedback adoption to higher-income patient segments and constrain total addressable market development beyond specialty private pay clinical settings.
Opportunity:
Remote and Home-Based Neurofeedback Delivery
Remote and home-based neurofeedback delivery represents a transformational access expansion opportunity as affordable consumer-grade EEG headsets and telehealth platform integration enable supervised at-home training programs that eliminate geographic access barriers and session attendance burden for patients in underserved rural or mobility-constrained populations. Digital therapeutics regulatory frameworks emerging in Germany, Japan, and the United States are creating reimbursement pathways for prescription digital neurofeedback programs delivered through certified platform subscriptions. Home training economics with dramatically reduced per-session cost compared to clinic-based protocols are expanding the viable patient population for sustained neurofeedback intervention at scale.
Threat:
Competing Digital Therapeutics Modalities
Competition from FDA-cleared digital therapeutic applications addressing ADHD, anxiety, and depression through cognitive behavioral therapy, biofeedback, and gamified behavioral intervention modalities represents a growing commercial threat as competing platforms with stronger clinical evidence bases may preferentially capture reimbursement coverage and physician recommendation at the expense of neurofeedback alternatives. Pharmaceutical company digital therapy partnerships creating bundled medication and digital support programs are generating competing reimbursement-supported access pathways that independent neurofeedback platform operators cannot match without equivalent commercial infrastructure. Direct-to-consumer meditation and mindfulness apps capturing discretionary mental wellness spending are competing for the same consumer time and budget allocation as consumer neurofeedback subscriptions.
Covid-19 Impact:
COVID-19 generated a significant mental health crisis that substantially expanded public awareness and treatment-seeking behavior for ADHD, anxiety, and stress-related conditions that neurofeedback platforms address, creating demand growth that persisted well beyond initial pandemic phases. Telehealth regulatory liberalizations during the pandemic period enabled remote neurofeedback session delivery that expanded clinician and patient familiarity with digital mental health intervention modalities. Post-pandemic investment in mental health technology platforms has sustained capital availability for neurofeedback platform development and commercialization programs that benefited from pandemic-era digital health investor attention.
The services segment is expected to be the largest during the forecast period
The services segment is expected to account for the largest market share during the forecast period, due to the subscription-based clinical session delivery model generating recurring revenue that substantially exceeds one-time hardware procurement values in established neurofeedback practice accounts. Platform operators providing comprehensive session management, clinician training certification, protocol library access, and patient progress analytics through managed service arrangements are achieving superior customer retention and lifetime account revenue versus hardware-only vendor relationships. Teletherapy delivery expansion is increasing the volume of billable neurofeedback sessions per platform installation, amplifying services revenue growth relative to hardware and software segments.
The EEG neurofeedback segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the EEG neurofeedback segment is predicted to witness the highest growth rate, driven by rapidly declining consumer EEG headset costs that are expanding the addressable clinical and home-use market, growing clinical protocol standardization improving treatment outcome consistency, and expanding insurance reimbursement coverage in major markets recognizing EEG neurofeedback for ADHD and anxiety indications. Wireless dry-electrode EEG systems eliminating gel preparation burden are significantly improving patient acceptance and session compliance rates that improve clinical outcome evidence for reimbursement negotiations. Smartphone-connected EEG systems enabling continuous home training between clinic sessions are generating new subscription revenue streams beyond traditional office-based session billing models.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to the high ADHD diagnosis and treatment rate in the United States generating large clinical demand, growing insurance plan coverage for neurofeedback ADHD treatment, and established clinical neurofeedback practitioner community adopting digital platform tools. U.S.-based neurofeedback platform companies including BrainMaster Technologies and BrainTrain Inc. maintain established clinical customer bases. Strong mental health technology investment ecosystem and digital health reimbursement framework development in the United States sustains North American platform innovation and commercial leadership.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing awareness of ADHD and mental health treatment options across previously underserved populations, expanding healthcare infrastructure enabling neurofeedback clinical service delivery, and government mental health investment programs in China, Japan, Australia, and South Korea. Rising ADHD diagnosis rates as psychiatric assessment infrastructure develops across Asia Pacific markets are generating growing clinical platform procurement demand. Domestic neurofeedback platform developer ecosystem emergence in China and South Korea is building regional market capacity.
Key players in the market
Some of the key players in Neurofeedback Platforms Market include BrainMaster Technologies, Thought Technology Ltd., NeuroCare Group, Mitsar Co. Ltd., EEGer, BrainTrain Inc., Neurofield Inc., Zengar Institute, Cygnet Software, Neurobit Systems, Emotiv Inc., OpenBCI, Natus Medical, Compumedics Neuroscan, Advanced Brain Monitoring, ANT Neuro, NeuroSky, and BrainCo.
Key Developments:
In March 2026, OpenBCI introduced the Galea Gen 2 multimodal biosensing headset combining EEG, EMG, and eye tracking for combined neurofeedback and biofeedback research and clinical training protocols.
In February 2026, Thought Technology Ltd. released the ProComp Infiniti 8 multichannel biofeedback and neurofeedback system with enhanced wireless EEG acquisition and integrated teletherapy session delivery capabilities.
In December 2025, NeuroCare Group launched its cloud-based neurofeedback protocol management platform integrating AI-driven session personalization and remote therapist supervision for multi-site clinical network deployment.
Components Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
ADHD and Mental Health Treatment Demand
Escalating ADHD and mental health treatment demand is the primary driver expanding neurofeedback platform adoption as clinicians and patients seek non-pharmacological, side-effect-free interventions for attention deficit disorders, anxiety, and depression that medication-resistant patient populations particularly require. FDA clearance of neurofeedback-based ADHD treatments has established regulatory legitimacy that is expanding insurance reimbursement coverage and physician referral confidence. Growing parental preference for non-stimulant ADHD interventions for pediatric patients is generating strong consumer demand for certified clinical neurofeedback programs that creates sustained platform procurement growth across clinical psychology and pediatric neurology practice settings.
Restraint:
Clinical Evidence and Reimbursement Gaps
Inconsistent clinical evidence quality and limited insurance reimbursement coverage represent significant adoption barriers as neurofeedback platform operators struggle to secure payer coverage without the randomized controlled trial evidence bases that health technology assessment bodies require for positive coverage determinations. Heterogeneity of neurofeedback protocols, electrode placement standards, and outcome measurement approaches across clinical studies limits meta-analytic evidence synthesis that would strengthen reimbursement advocacy. High out-of-pocket session costs in markets without coverage create access barriers that confine neurofeedback adoption to higher-income patient segments and constrain total addressable market development beyond specialty private pay clinical settings.
Opportunity:
Remote and Home-Based Neurofeedback Delivery
Remote and home-based neurofeedback delivery represents a transformational access expansion opportunity as affordable consumer-grade EEG headsets and telehealth platform integration enable supervised at-home training programs that eliminate geographic access barriers and session attendance burden for patients in underserved rural or mobility-constrained populations. Digital therapeutics regulatory frameworks emerging in Germany, Japan, and the United States are creating reimbursement pathways for prescription digital neurofeedback programs delivered through certified platform subscriptions. Home training economics with dramatically reduced per-session cost compared to clinic-based protocols are expanding the viable patient population for sustained neurofeedback intervention at scale.
Threat:
Competing Digital Therapeutics Modalities
Competition from FDA-cleared digital therapeutic applications addressing ADHD, anxiety, and depression through cognitive behavioral therapy, biofeedback, and gamified behavioral intervention modalities represents a growing commercial threat as competing platforms with stronger clinical evidence bases may preferentially capture reimbursement coverage and physician recommendation at the expense of neurofeedback alternatives. Pharmaceutical company digital therapy partnerships creating bundled medication and digital support programs are generating competing reimbursement-supported access pathways that independent neurofeedback platform operators cannot match without equivalent commercial infrastructure. Direct-to-consumer meditation and mindfulness apps capturing discretionary mental wellness spending are competing for the same consumer time and budget allocation as consumer neurofeedback subscriptions.
Covid-19 Impact:
COVID-19 generated a significant mental health crisis that substantially expanded public awareness and treatment-seeking behavior for ADHD, anxiety, and stress-related conditions that neurofeedback platforms address, creating demand growth that persisted well beyond initial pandemic phases. Telehealth regulatory liberalizations during the pandemic period enabled remote neurofeedback session delivery that expanded clinician and patient familiarity with digital mental health intervention modalities. Post-pandemic investment in mental health technology platforms has sustained capital availability for neurofeedback platform development and commercialization programs that benefited from pandemic-era digital health investor attention.
The services segment is expected to be the largest during the forecast period
The services segment is expected to account for the largest market share during the forecast period, due to the subscription-based clinical session delivery model generating recurring revenue that substantially exceeds one-time hardware procurement values in established neurofeedback practice accounts. Platform operators providing comprehensive session management, clinician training certification, protocol library access, and patient progress analytics through managed service arrangements are achieving superior customer retention and lifetime account revenue versus hardware-only vendor relationships. Teletherapy delivery expansion is increasing the volume of billable neurofeedback sessions per platform installation, amplifying services revenue growth relative to hardware and software segments.
The EEG neurofeedback segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the EEG neurofeedback segment is predicted to witness the highest growth rate, driven by rapidly declining consumer EEG headset costs that are expanding the addressable clinical and home-use market, growing clinical protocol standardization improving treatment outcome consistency, and expanding insurance reimbursement coverage in major markets recognizing EEG neurofeedback for ADHD and anxiety indications. Wireless dry-electrode EEG systems eliminating gel preparation burden are significantly improving patient acceptance and session compliance rates that improve clinical outcome evidence for reimbursement negotiations. Smartphone-connected EEG systems enabling continuous home training between clinic sessions are generating new subscription revenue streams beyond traditional office-based session billing models.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to the high ADHD diagnosis and treatment rate in the United States generating large clinical demand, growing insurance plan coverage for neurofeedback ADHD treatment, and established clinical neurofeedback practitioner community adopting digital platform tools. U.S.-based neurofeedback platform companies including BrainMaster Technologies and BrainTrain Inc. maintain established clinical customer bases. Strong mental health technology investment ecosystem and digital health reimbursement framework development in the United States sustains North American platform innovation and commercial leadership.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing awareness of ADHD and mental health treatment options across previously underserved populations, expanding healthcare infrastructure enabling neurofeedback clinical service delivery, and government mental health investment programs in China, Japan, Australia, and South Korea. Rising ADHD diagnosis rates as psychiatric assessment infrastructure develops across Asia Pacific markets are generating growing clinical platform procurement demand. Domestic neurofeedback platform developer ecosystem emergence in China and South Korea is building regional market capacity.
Key players in the market
Some of the key players in Neurofeedback Platforms Market include BrainMaster Technologies, Thought Technology Ltd., NeuroCare Group, Mitsar Co. Ltd., EEGer, BrainTrain Inc., Neurofield Inc., Zengar Institute, Cygnet Software, Neurobit Systems, Emotiv Inc., OpenBCI, Natus Medical, Compumedics Neuroscan, Advanced Brain Monitoring, ANT Neuro, NeuroSky, and BrainCo.
Key Developments:
In March 2026, OpenBCI introduced the Galea Gen 2 multimodal biosensing headset combining EEG, EMG, and eye tracking for combined neurofeedback and biofeedback research and clinical training protocols.
In February 2026, Thought Technology Ltd. released the ProComp Infiniti 8 multichannel biofeedback and neurofeedback system with enhanced wireless EEG acquisition and integrated teletherapy session delivery capabilities.
In December 2025, NeuroCare Group launched its cloud-based neurofeedback protocol management platform integrating AI-driven session personalization and remote therapist supervision for multi-site clinical network deployment.
Components Covered:
- Hardware
- Software
- Services
- EEG Neurofeedback
- fMRI Neurofeedback
- HEG Neurofeedback
- SCP Neurofeedback
- Standalone Systems
- Cloud-Based Platforms
- Pediatric
- Adults
- Geriatric
- ADHD Treatment
- Anxiety & Depression Management
- Sleep Disorders
- Cognitive Enhancement
- Pain Management
- Other Applications
- Hospitals & Clinics
- Wellness Centers
- Research Institutions
- Home Users
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY COMPONENT
5.1 Hardware
5.1.1 Electrode Type
5.2 Software
5.3 Services
6 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY MODALITY
6.1 EEG Neurofeedback
6.2 fMRI Neurofeedback
6.3 HEG Neurofeedback
6.4 SCP Neurofeedback
7 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY PLATFORM TYPE
7.1 Standalone Systems
7.2 Cloud-Based Platforms
8 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY AGE GROUP
8.1 Pediatric
8.2 Adults
8.3 Geriatric
9 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY APPLICATION
9.1 ADHD Treatment
9.2 Anxiety & Depression Management
9.3 Sleep Disorders
9.4 Cognitive Enhancement
9.5 Pain Management
9.6 Other Applications
10 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY END USER
10.1 Hospitals & Clinics
10.2 Wellness Centers
10.3 Research Institutions
10.4 Home Users
10.5 Other End Users
11 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 KEY DEVELOPMENTS
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 COMPANY PROFILING
13.1 BrainMaster Technologies
13.2 Thought Technology Ltd.
13.3 NeuroCare Group
13.4 Mitsar Co. Ltd.
13.5 EEGer
13.6 BrainTrain Inc.
13.7 Neurofield Inc.
13.8 Zengar Institute
13.9 Cygnet Software
13.10 Neurobit Systems
13.11 Emotiv Inc.
13.12 OpenBCI
13.13 Natus Medical
13.14 Compumedics Neuroscan
13.15 Advanced Brain Monitoring
13.16 ANT Neuro
13.17 NeuroSky
13.18 BrainCo
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY COMPONENT
5.1 Hardware
5.1.1 Electrode Type
5.2 Software
5.3 Services
6 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY MODALITY
6.1 EEG Neurofeedback
6.2 fMRI Neurofeedback
6.3 HEG Neurofeedback
6.4 SCP Neurofeedback
7 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY PLATFORM TYPE
7.1 Standalone Systems
7.2 Cloud-Based Platforms
8 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY AGE GROUP
8.1 Pediatric
8.2 Adults
8.3 Geriatric
9 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY APPLICATION
9.1 ADHD Treatment
9.2 Anxiety & Depression Management
9.3 Sleep Disorders
9.4 Cognitive Enhancement
9.5 Pain Management
9.6 Other Applications
10 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY END USER
10.1 Hospitals & Clinics
10.2 Wellness Centers
10.3 Research Institutions
10.4 Home Users
10.5 Other End Users
11 GLOBAL NEUROFEEDBACK PLATFORMS MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 KEY DEVELOPMENTS
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 COMPANY PROFILING
13.1 BrainMaster Technologies
13.2 Thought Technology Ltd.
13.3 NeuroCare Group
13.4 Mitsar Co. Ltd.
13.5 EEGer
13.6 BrainTrain Inc.
13.7 Neurofield Inc.
13.8 Zengar Institute
13.9 Cygnet Software
13.10 Neurobit Systems
13.11 Emotiv Inc.
13.12 OpenBCI
13.13 Natus Medical
13.14 Compumedics Neuroscan
13.15 Advanced Brain Monitoring
13.16 ANT Neuro
13.17 NeuroSky
13.18 BrainCo
LIST OF TABLES
Table 1 Global Neurofeedback Platforms Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Neurofeedback Platforms Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global Neurofeedback Platforms Market Outlook, By Hardware (2023-2034) ($MN)
Table 4 Global Neurofeedback Platforms Market Outlook, By Electrode Type (2023-2034) ($MN)
Table 5 Global Neurofeedback Platforms Market Outlook, By Software (2023-2034) ($MN)
Table 6 Global Neurofeedback Platforms Market Outlook, By Services (2023-2034) ($MN)
Table 7 Global Neurofeedback Platforms Market Outlook, By Modality (2023-2034) ($MN)
Table 8 Global Neurofeedback Platforms Market Outlook, By EEG Neurofeedback (2023-2034) ($MN)
Table 9 Global Neurofeedback Platforms Market Outlook, By fMRI Neurofeedback (2023-2034) ($MN)
Table 10 Global Neurofeedback Platforms Market Outlook, By HEG Neurofeedback (2023-2034) ($MN)
Table 11 Global Neurofeedback Platforms Market Outlook, By SCP Neurofeedback (2023-2034) ($MN)
Table 12 Global Neurofeedback Platforms Market Outlook, By Platform Type (2023-2034) ($MN)
Table 13 Global Neurofeedback Platforms Market Outlook, By Standalone Systems (2023-2034) ($MN)
Table 14 Global Neurofeedback Platforms Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
Table 15 Global Neurofeedback Platforms Market Outlook, By Age Group (2023-2034) ($MN)
Table 16 Global Neurofeedback Platforms Market Outlook, By Pediatric (2023-2034) ($MN)
Table 17 Global Neurofeedback Platforms Market Outlook, By Adults (2023-2034) ($MN)
Table 18 Global Neurofeedback Platforms Market Outlook, By Geriatric (2023-2034) ($MN)
Table 19 Global Neurofeedback Platforms Market Outlook, By Application (2023-2034) ($MN)
Table 20 Global Neurofeedback Platforms Market Outlook, By ADHD Treatment (2023-2034) ($MN)
Table 21 Global Neurofeedback Platforms Market Outlook, By Anxiety & Depression Management (2023-2034) ($MN)
Table 22 Global Neurofeedback Platforms Market Outlook, By Sleep Disorders (2023-2034) ($MN)
Table 23 Global Neurofeedback Platforms Market Outlook, By Cognitive Enhancement (2023-2034) ($MN)
Table 24 Global Neurofeedback Platforms Market Outlook, By Pain Management (2023-2034) ($MN)
Table 25 Global Neurofeedback Platforms Market Outlook, By Other Applications (2023-2034) ($MN)
Table 26 Global Neurofeedback Platforms Market Outlook, By End User (2023-2034) ($MN)
Table 27 Global Neurofeedback Platforms Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 28 Global Neurofeedback Platforms Market Outlook, By Wellness Centers (2023-2034) ($MN)
Table 29 Global Neurofeedback Platforms Market Outlook, By Research Institutions (2023-2034) ($MN)
Table 30 Global Neurofeedback Platforms Market Outlook, By Home Users (2023-2034) ($MN)
Table 31 Global Neurofeedback Platforms Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global Neurofeedback Platforms Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Neurofeedback Platforms Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global Neurofeedback Platforms Market Outlook, By Hardware (2023-2034) ($MN)
Table 4 Global Neurofeedback Platforms Market Outlook, By Electrode Type (2023-2034) ($MN)
Table 5 Global Neurofeedback Platforms Market Outlook, By Software (2023-2034) ($MN)
Table 6 Global Neurofeedback Platforms Market Outlook, By Services (2023-2034) ($MN)
Table 7 Global Neurofeedback Platforms Market Outlook, By Modality (2023-2034) ($MN)
Table 8 Global Neurofeedback Platforms Market Outlook, By EEG Neurofeedback (2023-2034) ($MN)
Table 9 Global Neurofeedback Platforms Market Outlook, By fMRI Neurofeedback (2023-2034) ($MN)
Table 10 Global Neurofeedback Platforms Market Outlook, By HEG Neurofeedback (2023-2034) ($MN)
Table 11 Global Neurofeedback Platforms Market Outlook, By SCP Neurofeedback (2023-2034) ($MN)
Table 12 Global Neurofeedback Platforms Market Outlook, By Platform Type (2023-2034) ($MN)
Table 13 Global Neurofeedback Platforms Market Outlook, By Standalone Systems (2023-2034) ($MN)
Table 14 Global Neurofeedback Platforms Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
Table 15 Global Neurofeedback Platforms Market Outlook, By Age Group (2023-2034) ($MN)
Table 16 Global Neurofeedback Platforms Market Outlook, By Pediatric (2023-2034) ($MN)
Table 17 Global Neurofeedback Platforms Market Outlook, By Adults (2023-2034) ($MN)
Table 18 Global Neurofeedback Platforms Market Outlook, By Geriatric (2023-2034) ($MN)
Table 19 Global Neurofeedback Platforms Market Outlook, By Application (2023-2034) ($MN)
Table 20 Global Neurofeedback Platforms Market Outlook, By ADHD Treatment (2023-2034) ($MN)
Table 21 Global Neurofeedback Platforms Market Outlook, By Anxiety & Depression Management (2023-2034) ($MN)
Table 22 Global Neurofeedback Platforms Market Outlook, By Sleep Disorders (2023-2034) ($MN)
Table 23 Global Neurofeedback Platforms Market Outlook, By Cognitive Enhancement (2023-2034) ($MN)
Table 24 Global Neurofeedback Platforms Market Outlook, By Pain Management (2023-2034) ($MN)
Table 25 Global Neurofeedback Platforms Market Outlook, By Other Applications (2023-2034) ($MN)
Table 26 Global Neurofeedback Platforms Market Outlook, By End User (2023-2034) ($MN)
Table 27 Global Neurofeedback Platforms Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 28 Global Neurofeedback Platforms Market Outlook, By Wellness Centers (2023-2034) ($MN)
Table 29 Global Neurofeedback Platforms Market Outlook, By Research Institutions (2023-2034) ($MN)
Table 30 Global Neurofeedback Platforms Market Outlook, By Home Users (2023-2034) ($MN)
Table 31 Global Neurofeedback Platforms Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
